Heading into 3Q21 earnings, one of the top debates for our coverage is the China region – and changes in policy which may encourage “buy local” initiatives in Diagnostics. Diagnostics experts  Dr. Mao Mao and Ms. Camille Hu joined us for a discussion and provided an on-the-ground view as to what is happening in the market. Topics of discussion included:

1) An overview on how the Chinese national government, local provinces and cities approach Diagnostics purchasing

2) Recent updates around procurement initiatives in the Diagnostics industry

3) Perceptions of Western multi-national companies in the region

4) An overview on the key local manufacturers, and how they compete with multi-nationals

5) An update on the sequencing market, and competition for Illumina from BGI